Lumos Pharma Inc (LUMO) - News Archive

AUSTIN, Texas and GREENWICH, Conn. Dec. 12, 2024 — In a significant development within the biopharmaceutical landscape, Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage company dedicated to developing therapeutics for...

Sustained Growth Data for LUM-201 in Pediatric Growth Hormone Deficiency Presented at ESPE 2024AUSTIN, Texas, November 21, 2024 Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company specializing...

In a significant development for pediatric growth hormone deficiency (PGHD) treatment, Lumos Pharma Inc. (NASDAQ: LUMO) has announced that it has received the green light from the U.S. Food and Drug Administration (FDA)...

Lumos Pharma Enhances Pediatric Growth Hormone Deficiency Research: Presentation at APPES 2024 Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical organization dedicated to addressing therapeutics for r...

Austin, Texas, September 5, 2024 Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic solutions for rare diseases, is poised to make a significant...

The biopharmaceutical industry has witnessed significant developments in recent times with companies like BridgeBio Pharma and Lumos Pharma making significant breakthroughs in rare disease therapeutics. This article wil...

Lumos Pharma, a clinical-stage biopharmaceutical company specializing in rare disease therapeutics, has revealed fresh analyses of data from its Phase 2 OraGrowtH212 clinical trial. The findings were presented at the 20...

Lumos Pharma Announces s Accepted for Presentation at ENDO 2024Lumos Pharma, a clinical stage biopharmaceutical company dedicated to developing therapeutics for rare diseases, has recently announced that new data analys...

In a groundbreaking development, Lumos Pharma, a leading biopharmaceutical company focused on pediatric healthcare, has announced the grant of patent protection by the United States Patent and Trade Office (USPTO) for i...